CHEMED CORP 8K

Chemed Corporation reported strong second-quarter 2026 results led by VITAS outperformance, executed substantial share repurchases, entered a new $450 million credit facility, and raised full-year 2026 adjusted EPS guidance to $25.00–$25.75 per diluted share.

On July 28, 2026, Chemed Corporation reported its financial results for the second quarter ended June 30, 2026, highlighting consolidated revenue growth of 8.8% to $673.3 million, a 43.7% increase in GAAP diluted EPS to $5.13 and a 41.9% increase in adjusted diluted EPS to $6.06, driven largely by strong performance at its VITAS hospice segment, which saw 11.9% net patient revenue growth, higher admissions and materially reduced Medicare Cap charges versus the prior year. The company also disclosed that Roto-Rooter delivered modest 3.3% revenue growth with essentially flat adjusted EBITDA and some margin compression, while Chemed’s balance sheet reflected $40.2 million in cash and $140.0 million in long-term debt. During the quarter, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement featuring a $450 million revolver and a $250 million expansion feature at a floating SOFR plus 100 bps rate, leaving approximately $262.7 million of undrawn borrowing capacity net of letters of credit. The company was active in capital returns, repurchasing 210,000 shares for $89.8 million in the quarter and 1,517,500 shares over the trailing 12 months, reducing its share count by about 10.5% with $139.8 million remaining under its repurchase authorization. Reflecting VITAS outperformance and the impact of share repurchases, Chemed raised its full-year 2026 adjusted diluted EPS guidance to a range of $25.00 to $25.75 from $24.00 to $24.75, implying roughly 17.8% growth over 2025 at the midpoint, while reiterating Roto-Rooter’s expected 2026 revenue growth of 3.0% to 3.5% and adjusted EBITDA margin of 21.5% to 22.5%.

Filing Facts

CIK

19584

Ticker

-

Form

8K

Source Type

sec

Accession

0000019584-26-000018

Alert Tier

7